Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.

Publication Title

Rev Urol

Authors

Christopher M Pieczonka
Przemyslaw Twardowski, Providence Hospital Santa Monica Santa Monica, CAFollow
Joseph Renzulli
Jason Hafron
Deborah M Boldt-Houle
Stuart Atkinson
Scott Eggener

Document Type

Article

Publication Date

1-1-2018

Keywords

Androgen deprivation therapy; LHRH agonist; Leuprolide acetate; Nadir testosterone; Prostate cancer

Abstract

Evidence suggests lower nadir testosterone levels during the first year of androgen deprivation therapy improve advanced prostate cancer clinical outcomes. We evaluated pivotal trials for subcutaneously administered leuprolide acetate (1-, 3-, 4-, and 6-month doses) to determine nadir testosterone levels. Pooled analysis showed 99%, 97%, and 91% of patients reached nadir testosterone ≤20, ≤10, and ≤5 ng/dL respectively (median ≤3 ng/dL). Across all available categories, $88% of patients reached nadir testosterone ≤5 ng/dL, and

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology